top of page

The New Standard
in Ophthalmology

Enrolling for Phase III

You may qualify to participate in a clinical trial.

New Ocular Therapeutic Options for Unmet Needs in Ophthalmology

Expanded Access Announcement:

The study drug is available to patients who:

  • Have severe, vision-threatening chronic oGVHD

  • Have no satisfactory alternative treatments

  • Are not eligible to participate in ongoing clinical trials.

Click the PDF to see the offical letter announcement

About Regenerative Ocular Immunobiologics

Regenerative Ocular Immunobiologics (ROI) is a cutting-edge biotechnology company that is pioneering new therapeutic options in the field of ophthalmology. The company's primary focus is on developing regenerative medicine that can treat ocular graft versus host disease (oGVHD).

​

The company is poised to make a significant impact on the lives of patients suffering from these debilitating diseases.

Learn More
bottom of page